Zura Bio Limited
NASDAQ:ZURABiotechnology
+$0.07 today
- Market cap
- $92.96M
- Beta
- 0.03
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.67
Volume 3.02M
Average 0.75M
ZURA Income Tax Expense
Income taxes recognized for the period, including current and deferred tax.
Zura Bio LimitedNASDAQ: ZURA
Income Tax Expense · Q1 FY2026 · quarter ended Mar 2026
Income tax expense remains negative
Q1 FY2026 income tax expense was $0, compared with $0 a year earlier. Trailing-twelve-month income tax expense was $0.
Context
- Income tax expense increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly income tax expense holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Income Tax Expense history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Income Tax Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Income Tax Expense vs competitors
How ZURA compares with its peers on the latest reported figures
- ZURA's LTM Mar 2026 income tax expense of $0 is the 3rd highest of the 11 companies compared; the peer median is $0.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1.39M | +164.0% | — | 10.0% | |
| LTM Mar 2026 | $92K | +103.7% | — | 0.1% | |
ZURAZura Bio Limited | LTM Mar 2026 | $0 | — | — | — |
| LTM Mar 2026 | $0 | -100.0% | — | 0.0% | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $0 | — | — | — |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | +100.0% | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding ZURA) | $0 | +101.9% | — | 0.0% | |
Competitors are the stored peer set for ZURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 0 | 23.69M | 44M | 24.4M | 42.08M |
| Selling, General & Admin | 1.09M | 3.47M | 18.64M | 30.79M | 33.16M |
| Operating Expenses | 1.09M | 27.16M | 62.64M | 55.19M | 75.25M |
| Depreciation & Amortization | 0 | 0 | 0 | 9K | 49K |
| EBITDA | 8.42M | (27.33M) | (60.56M) | (52.39M) | (68.6M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (1.09M) | (27.16M) | (62.64M) | (55.19M) | (75.25M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 23.48K | 570 | 2.19M | 8M | 6.34M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 9.51M | (171K) | 2.08M | 2.79M | 6.6M |
| Income Before Tax | 8.42M | (27.33M) | (60.56M) | (52.4M) | (68.65M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | 8.42M | (25.74M) | (60.36M) | (52.4M) | (68.65M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | 0.40 | 0.21 | (2.09) | (0.60) | (1.06) |
| EPS (Diluted) | 0.40 | 0.21 | (2.09) | (0.60) | (1.06) |
| Weighted Avg Shares | 17.25M | 17.25M | 33.06M | 75.07M | 94.16M |
| Weighted Avg Shares (Diluted) | 17.25M | 17.25M | 33.06M | 75.07M | 94.16M |
Zura Bio Limited
NASDAQ:ZURA
Intrinsic Alpha fair value
Locked
Current Price
$0.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.